Oscotec plans to transfer acute myeloid leukemia treatment technology to global pharmaceutical companies

Published: 2014-02-20 16:14:10

Updated: 2014-02-20 16:14:10

New drug developing company Oscotec announced that the anti-cancer effects of next generation acute myeloid leukemia therapeutic drug candidate 'G-749' was published in the world's leading research journal in the field of blood 'Blood', February issue online edition.

According to the company, this new drug candidate is a small molecule compound that inhibit FLT3 which is one of protein kinase,...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.